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Abstract
AIM: To character ize cytogenet ic al terat ions in 
esophageal squamous cell carcinoma (ESCC) and its 
metastasis.
METHODS: A total of 37 cases of primary ESCC and 
15 pairs of primary ESCC tumors and their matched 
metastatic lymph nodes cases were enrolled from 
Linzhou, the high incidence area for ESCC in Henan, 
northern China. The comparative genomic hybridization 
(CGH) was applied to determine the chromosomal 
aberrations on the DNA extracted from the frozen ESCC 
and metastatic lymph node samples from these patients.
RESULTS: CGH showed chromosomal aberrations in all 
the cases. In 37 cases of primary ESCC, chromosomal 
profile of DNA copy number was characterized by 
frequently detected gains at 8q (29/37, 78%), 3q (24/37, 
65%), 5p (19/37, 51%); and frequently detected losses 
at 3p (21/37, 57%), 8p and 9q (14/37, 38%). In 15 pairs 
of primary ESCC tumors and their matched metastatic 
lymph node cases, the majority of the chromosomal 
aberrations in both primary tumor and metastatic lymph 
node lesions were consistent with the primary ESCC 
cases, but new candidate regions of interest were also 
detected. The most significant finding is the gains of 
chromosome 6p with a minimum high-level amplification 
region at 6p12-6q12 in 7 metastatic lymph nodes but 
only in 2 corresponding primary tumors (P  = 0.05) and 
20p with a minimum high-level amplification region 
at 20p12 in 11 metastatic lymph nodes but only in 5 
corresponding primary tumors (P  < 0.05). Another 
interesting finding is the loss of chromosome 10p and 
10q in 8 and 7 metastatic lymph nodes but only in 2 
corresponding primary tumors (P < 0.05). 
CONCLUSION: Using the CGH technique to detect 
chromosomal aberrations in both the primary tumor 
and its metastatic lymph nodes of ESCC, gains of 8q, 3q 
and 5p and loss of 3p, 8p, 9q and 13q were specifically 
implicated in ESCC in Linzhou population. Gains of 6p 
and 20p and loss of 10pq may contribute to the lymph 
node metastasis of ESCC. These findings suggest that 
the gains and losses of chromosomal regions may 
contain ESCC-related oncogenes and tumor suppressor 
genes and provide important theoretic information for 
identifying and cloning novel ESCC-related oncogenes 
and tumor suppressor genes.
© 2008 WJG. All rights reserved.
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INTRODUCTION
Advances in diagnostic and therapeutic modalities for 
malignancies have improved the survival of  cancer 
patients. However, the mortality rate of  patients with 
esophageal squamous cell carcinoma (ESCC) is still very 
high due to its highly invasive nature and potential to 
metastasize to lymph nodes and distant organs. ESCC 
is one of  the leading causes of  cancer-related death 
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in Linxian, Henan Province in northern China, with a 
mortality rate of  161/100 000 for male and 103/100 000 
for female. Recent studies by us and other authors 
have indicated multiple genetic alterations underlying 
the multistage carcinogenesis of  ESCC, such as p53-
Rb pathway[1]. However, the mechanisms of  human 
esophageal multistage carcinogenesis in this area, especially 
the difference in genetic changes between primary ESCC 
and lymph node metastasis, are largely unknown. 
Comparative genomic hybridization (CGH) analysis 
can provide comprehensive information about relative 
chromosomal losses and gains in malignant tumors in vitro[2]. 
This technique can detect the changes of  recurrent 
copy number and may highlight chromosomal regions 
containing genes that contribute to cancer development 
and/or progression. In this study, we used CGH analysis to 
examine 37 primary ESCC and 15 pairs of  primary ESCC 
tumors and their corresponding metastatic lymph nodes, 
to elucidate the genetic pathway of  carcinogenesis and to 
clarify the metastatic mechanisms of  genetic aberrations in 
ESCC. 
MATERIALS AND METHODS
The 37 primary tumor samples and 15 pairs of  primary 
ESCC and their matched lymph node metastasis in this 
study were all from Linzhou, Henan, the high incidence 
area for ESCC. The primary specimen for each patient 
was collected at the time of  surgical resection at the 
Department of  Surgery, Yiaochun Hospital and Linzhou 
Hospital. All the patients underwent esophagectomy 
without preoperative radiotherapy and/or chemotherapy. 
Tumor tissue specimens were frozen in liquid nitrogen and 
kept in a freezer at -80℃ until use.
Microdissection and DNA extraction
Tumor tissue was selected by histopathologic examination 
on the basis of  estimated more than 80% cancer cells. 
The metastatic lymph nodes were embedded in OTC and 
cryosected into 15 μm serial slides under -20℃. For DNA 
extraction, we cut 22 serial 15 μm sections. The first and 
last ones were used for hematoxylin-eosin (HE) staining, 
and the remain 20 were lightly stained with hematoxylin. 
Under microscopic (MZ 12, Leica, Bensheim, Germany) 
observation, tumor tissues were microdissected manually 
from surrounding stromal tissues and normal cells with a 
disposable fine needle, and tissue fragments were collected 
and transferred into a microtube.
Genomic DNA was extracted from tumor specimens 
by proteinase K/sodium dodecyl sulfate digestion followed 
by phenol/chloroform/alcohol extraction. Normal 
reference DNA was prepared from peripheral blood 
lymphocytes of  healthy donors.
Slide preparation
Metaphase chromosome spreads were prepared from 
peripheral blood leukocytes of  healthy donors. Blood cells 
were cultured for 72 h in RPMI1640 containing 15% fetal 
bovine serum and penicillin-streptomycin (PHA 5 μg/mL). 
Blood cells were harvested by arresting with Colcemid 
(0.05 g/L) for 1h, followed by hypotonic treatment in KCl 
(0.075 mmol/L) for 20 min on ice and fixation in cold 
methanol: acetic acid (3:1).
Comparative genomic hybridization(CGH)
CGH was performed essentially as described previously[2]. 
Briefly, genomic DNA from a tumor sample and a sex-
matched normal reference was labeled directly with 
Spectrum Green-dUTP and SpectrumRed-dUTP (Vysis, 
Downers Grove, IL, USA) by nick translation. Two 
hundred nanograms of  labeled tumor DNA and normal 
DNA probes were used in a 10 μL hybridization mixture 
(containing 55% formamide, 2 × SSC), and 10 μg human 
CotI DNA, which was denatured at 75℃ for 5 min. 
The slide containing normal metaphase spreads was 
treated with RNase (100 mg/L) at 37℃ for 1 h and then 
denatured at 75℃ in 70% formamide, and 2 × SSC for 
5 min. Hybridization with probes was then carried out 
at 37℃ in a moist chamber for 72 h. The slide was then 
washed in 0.4 × SSC/0.3% NP-40 at 75℃ for 2 min and 
then in 2 × SSC/0.1% NP-40 at room temperature 
for 2 min. After washing, the slide was counterstained with 
1 mg/L DAPI in an antifade solution. 
Digital image analysis
The hybridized metaphase chromosomes were analyzed 
using a digital image analysis system containing a Zeiss 
Axiophot microscope equipped with a Metachrome Ⅱ
cool-charged device camera (Photometics, AZ). Three 
images of  each metaphase were captured using filter wheel-
mounted, single band excitation Rhodamine, FITC, and 
DAPI filters. The image analyses were carried out using 
Quips CGH Analysis software (Vysis). Five metaphases 
were analyzed to generate fluorescence ratio profiles in 
each case. Interpretation of  the profiles was performed 
according to the program guidelines. The thresholds used 
for interpretation of  gains and losses of  a DNA sequence 
copy number was defined as a tumor/reference ratio 
greater than 1.25 or less than 0.75, respectively, by both the 
standard and the reverse hybridization methods.
Statistical analysis
We analyzed the genetic aberrations of  ESCC using the 
Fisher exact test for independence. Differences with a P value 
less than 0.05 were considered statistically significant.
RESULTS
CGH analysis
A total of  230 DNA copy number gains and 212 DNA 
copy number losses were found in 37 ESCC samples, with 
an average of  DNA copy number gains of  6.22 and DNA 
copy number losses of  5.73 per patient. In ESCC, the gain 
was most frequently detected on chromosome arms 8q 
(29/37, 78%), 3q (24/37, 65%) and 5p (19/37, 51%), (the 
chromosomal aberrant frequency on chromosome 6q, 7p 
and 7q was similar, all 38%), which was followed by (from 
high to low) 18p (12/37, 32%), 1q (11/37, 30%), 11q 
(10/37, 27%), 20q (10/37, 27%), 12p (9/37, 24%), 13q 
(6/37, 16%) and 18q (6/37, 16%). There were 20 cases 
with high copy number amplifications (tumor/reference 
ratio > 1.5), which were located on chromosome 1pter-
1p31, 1p11-1q22, 3q22-qter, 4p13-4q31, 5p, 6p12-6q14, 
8q, 9p, 11q12-11q23, 11q13-11q23, 16p11-16q21, 18pter-
18q12, 18p and 20p. The chromosomal profile of  DNA 
copy number losses was characterized as follows: the most 
frequently detected loss was on 3p (21/37, 57%), which 
was followed in turn (from high to low) by 8p (14/37, 
38%), 9q (14/37, 38%), 11q (13/37, 35%), 13q (13/37, 
35%), 5q (12/37, 32%), 1p (12/37, 32%), 4p (11/37, 30%), 
18q (11/37, 30%), 16q (10/37, 27%), 17p (10/37, 27%) 
and 19p (10/37, 27%). A summary of  genetic aberrations 
detected by CGH in ESCC is provided in Table 1 and 
Figure 1.
Differences in copy number alterations between 15 
pairs of primary ESCC and their matched lymph node 
metastasis 
A total of  102 gains and 90 losses were found in 15 
primary ESCC samples, with an average of  gains and 
losses per patient of  6.8 and 6.0, respectively, and 110 gains 
and 142 losses were found in 15 lymph nodes metastasis 
samples, with an average of  gains and losses per patient 
of  7.4 and 9.5. More genetic changes (252) were found in 
lymph nodes metastasis than in the corresponding primary 
lesions (192), especially the losses (9.5/case vs 6.0/case). 
The copy-number changes for the entire genome detected 
in these 15 primary ESCC and their corresponding 
metastatic lesions are summarized in Table 2 and Figure 2. 
In primary tumors, the most frequently detected sites of  
chromosome gain were 3q (15 of  15, 100%), 8q (11 of  
15, 73%), 1q (11 of  15, 73%), 12p (8 of  15, 53%), 18p (6 
of  15, 40%), 5p (7 of  15, 47%), 6p (7 of  15, 47%), 20p 
(11 of  15, 73%). In metastatic lymph nodes, the most 
frequently detected sites of  chromosome gain were 3q (14 
of  15, 93%), 8q (10 of  15, 67%), 1q (11 of  15, 73%), 12p 
(8 of  15, 53%), 18p (6 of  15, 40%), 5p (7 of  15, 47%), 6p 
(7 of  15, 47%), 20p (11 of  15, 73%). High copy-number 
amplification with a minimum gain 3q24-qter was detected 
in two primary tumors and six metastatic lymph nodes. 
The other three high copy-number amplifications of  6p21-
6q12 were detected only in metastatic lymph nodes but 
not in their corresponding primary tumors. The high copy-
number amplification of  20p was detected in metastatic 
lymph node lesions but not in their corresponding primary 
tumor. In primary tumors, the chromosomal profile of  
Table 1  CGH results of 37 ESCC cases, Linzhou, Henan
Case No. Gains Losses
66 908 5p, 10q11-10q21 3p21-3p11, 9,10q23-10qter, 15
66 865 1p31-1qter, 3q, 3q22-3qter, 5p, 6q15-6qter, 7p14-7qter, 8q13-qter, 18p 4pter-4p13, 9q, 5q11-14, 11p, 18q12-18qter
66 867 3q, 5pter-5q12, 6p12-6q12, 7p12-7qter, 8q, 16 3pter-3p13, 4q23-4qter, 8p, 9,11p13-11qter, 13,17p, Xp
66 909 3q, 5p, 7,8q12-8qter, 9p13-9qter, 19
66 755 1q, 2p, 3q, 8q, 9p, 11q13-11q21 1pter-1p31, 3pter-3p13, 8p, 11q22-11qter, 15,16,17,19,21,22
16 182 4p13-4qter, 8p12-8qter, 9p, 16p11-16qter, 16p11-16q21, 18p 1pter-1p32, 3p, 4pter-p14, 11q22-11qter, 18q, 19
66 907 2q14.1-14.3, 2q31-32, 3q23-3qter, 5p, 6q, 7p, 8,12p, 18p 3p, 4,5q, 10,11q21-qter, 12q, 17p, Xp
66 912 2q14-2qter, 3q22-3qter, 5p, 6p12-6q15, 8q, 12q11-12q22, 13,20q 1pter-1p31, 5q, 11pter-11q12, 16,17p, 19
66 910 6p21-6q13, 7q11-7q31, 8q, 13 1pter-1p31, 8p, 16q
66 948 2p, 3q, 3q22-3qter, 7,8q, 10p, 14,16q11-12 1pter-1p31, 3p, 6q, 8p, 11q14-11qter, 13,19,21
16 146 3q, 5pter-5q12, 6p21-6q12, 7q21-7q22, 8q, 17q, 18pter-18q11 8p, 9q, 16,18q12-18qter
16 634 3p12-3qter, 5pter-5q12, 7q21-7qter, 8q, 12p, 18p, 20,20p 1pter-1p33, 4pter-4p15, 9,11pter-11q12, 13,16q, 17,18q, 
19p, 21,22
16 179 1q, 3q, 3q22-3qter, 4p13-4q21, 5p, 6p, 7, 8q, 13 1pter-1p31, 3p, 5q, 8p, 9,10,14,19,Y
16 601 5p, 8p12-8qter,Y 3p, 19
16 605 6p, 8q, 11q11-11q21, 14,16pter-16q22, 17p, 20p11-20q13, 22 11q22-11qter, 18q12-18qter
16 609 1q, 2,3q, 3q22-3qter, 5p, 8q, 11p13-11q21, 12p, 13q21-13qter, 16q12-16qter 1p, 3p, 4,5q, 8p, 9p, 10,12q, 18p11-18qter, 21, Xp
16 610 3q, 7p, 8q, 12p12-12q23, 16p11-16q21, 18 1pter-1p31, 8pter-8p12, 11,17,19,Y
16 615 1q31-1qter, 2pter-2q33, 3q13-3qter, 4q12-4q21, 5p, 7q21-7q31, 8q22-8qter, 12,18p 2q34-2qter, 5q13-5q14, 7p11-7q11, 8p, 9,22, X
16 616 6p21-6qter, 7pter-7q21, 8p12-8qter, 10,14 7q22-7qter
16 629 1p32-1p21, 2q11-2q32, 3q22-3qter, 6p, 8q, 9p, 11p, 12q14-12q22, 18,20 2q33-2qter, 6q, 8p, 9q, 10q, 11q, 13,16, X
16 639 1p31-1p13, 3q13-3qter, 11q13-q23, 12pter-12q13, 14 3pter-13, 4pter-12, 5q21-qter, 21,22, Xpter-q13
16 658 3q, 4pter-4q13, 5p, 6p12-6q14, 8q 3p, 8p, 9q21-9qter, 11,19
16 721 1p11-1q22, 7pter-7q31, 14q21-14q23, 19,20 2p, 3p, 5q12-5qter, 6q, 11p, Y
16 740 5p13-5q13, 18pter-18q12 6pter-6p21, 14q13-14qter
19 110 1q21-1qter, 2q, 6,7p, 11p, 11q13-q22, 14, 16p13-16p11 1pter-1p34, 8pter-8q12, 8q23-8qter, 15q22-15qter, 16q, 17, 22
19 315 6p12-6q14, 13,16q11-16q21, 18pter-18q12 1p13-22, 3pter-q21, 8pter-12, 18q21-qter, X
19 419 2q24-2q32, 3q, 8,13,20 3p, 9p22-9q21, 10,16p, 17
16 172 8q22-8qter 13
16 181 3q13-3qter, 7,8,12,17,18p, 20,22 2q14-2q34, 3p, 4q, 5q11-q23, 6q11-24, 13
16 186 3p12-3qter, 5p, 6p21-6q15, 7, 8q, 11p14-11q14, 16,17pter-17q12, 20pter-20q11 13,18q
16 604 1p31-1qter, 3q, 4p12-4q12, 6, 7,8p22-8qter, 10pter-10q11, 11q12-11q23, 14q11-14q31 2pter-2q22, 3p, 5q21-5qter, 9p12-9qter, 13,15,17,18
16 624 1pter-1p31, 3pter-3p21, 3q, 5p, 6p21-6p12, 7p, 8q, 11,18pter-18q12, 19p13-19qter, 20 2p, 3p21-3p11, 4,5q, 8p, 10,14,16q, Y
16 633 8q22-23, 9,12p11-12q21, 21,X 3p, 6,10,11p, 12q21-12qter, 16q23-16qter, 18q,
16 632 1q, 2pter-q32, 3p12-qter, 5pter-q12, 8p22-qter, 9q, 11, 12pter-q13, 15, 16p12-q21, 
17p12-q24, 18pter-q12
3pter-3p13, 4,10,13
16 624 3q, 3q22-3qter, 5p, 11p11-11q13 3pter-3p12, 11q14-11qter, 13,18, X
16 625 1q, 3q, 4p14-4q21, 4q26-4qter, 19p11-19q13 1pter-1p319q33-9qter, 15,16,17p
66 945 1p31-1qter, 3q, 5p, 6q14-6qter, 8q12-8qter, 9pter-9q31 3p, 4,5q, 9q31-9qter, 11,13,14
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DNA copy number losses were 3p (10 of  15, 67%), 10p 
(2 of  15, 13%), 10q (2 of  15, 13%), 4q (6 of  15, 40%), 4p 
(7 of  15, 47%), 19p (8 of  15, 53%), 13q (4 of  15), 1p (7 
of  15), 17p and 18q (4 of  15, 27%). In metastatic lymph 
nodes, the chromosomal profiles of  DNA copy number 
losses were 3p (12 of  15, 80%), 10p (8 of  15, 53%), 10q (7 
of  15, 47%), 4q (10 of  15, 67%), 4p (9 of  15, 60%), 19p 
(10 of  15, 67%), 13q (8 of  15, 53%), 1p (7 of  15, 47%), 
17p and 18q (7 of  15, 47%).
Sta t i s t i ca l l y,  in  DNA copy number  g a ins  on 
chromosome 6p and 20p, there were significant differences 
between primary ESCC lesions and their corresponding 
lymph nodes (P < 0.05). In DNA copy number losses on 
chromosome 10pq, differences were significant between 
primary ESCC lesions and their corresponding lymph 
nodes (P < 0.05), (Table 3).
DISCUSSION
We have identified a genome-wide map of  genetic al-
terations in ESCC, and compared primary tumor and 
metastatic lymph nodes in this study. The majority of  the 
chromosomal aberrations in both primary tumor and met-
astatic lymph node lesions were consistent with the previ-
ous reports. For example, the gains of  3q, 5p, 8q23-ter 
and 20q and deletions of  3p25, 4p, 6q21, 9q22.3-q31, 9p, 
11q22-qter, 13q12-13, 18q22.3, and 19q had been detected 
as frequent chromosomal alterations in ESCC in at least 
one of  the previous CGH studies[3-6]. By comparing the 
primary ESCC with metastatic lymph nodes, we did detect 
new candidate regions of  interest, such as 6p, 20p and 
10pq, which may harbor the genes involved in lymph node 
metastasis.
The highest frequency of  DNA gain in ESCC occurred 
at chromosome 8q (78%), the chromosomal region at 8q 
harbors MYCC gene (8q24.1) which has been identified 
with a high frequency of  amplification in ESCC[7,8]. Gains 
of  3q were commonly seen in ESCC [9]. Possible candidate 
genes involved in tumor development include the genes 
for ribosomal protein L22 (RPL22), butyrylcholinesterase 
(BCHE), glucose transporter 2 (SLC2A2), transferring 
receptor (TFRC), thrombopoietin (THPO) and the 
phosphatidylinositol-3 kinase catalytic α-polypeptide 
(PIK3CA). Deletion of  9p and gain of  5p were seen 
Figure 1  Copy number alterations of 37 ESCC cases analyzed by CGH. Chromosomal regions of gain are on the right side of the chromosome ideograms, and regions of 
loss are on the left side.
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commonly in CGH studies of  patients with ESCC[3-5,9] and 
both are related to the progression of  ESCC[10,11]. hTERT 
on 5p is associated with the prognosis of  patients with 
carcinomas of  the breast, lung and ESCC as reported 
previously [10,12,13]. One of  the potential candidate genes in 
the region includes JS-1 and JK-1[13]. 
Deletion of  chromosome 3p is one of  the most 
frequent allelic imbalances in ESCC detected by CGH[3,4]. 
In our study, loss of  3p was detected in 65% in ESCC. 
Possible candidate tumor suppressor genes on these 
region were FHIT (fragile histidine triad)[15], catenin 
(CTNNB1)[16], and von Hippel-landau gene[17]. Our 
results of  proximal 3p loss mainly in ESSC may indicate 
a specific tumor suppressor gene at this locus involved 
in ESSC in high-risk areas. Loss of  8p was found in 38% 
of  ESCC cases. Deletion of  8p22-pter has been reported 
in patients with ESCC[5]. Mutations of  the Fasciculation 
and elongation protein zeta-1 (FEZ1) gene at 8p22 were 
found in patients with ESCC[18], and mutations of  two 
other genes in these regions, tumor necrosis factor-
related apoptosis-inducing ligand receptor 1 (TRAIL-R1) 
and receptor 2 (TRAIL-R2), were found in patients with 
metastatic breast carcinoma[19]. Loss of  17p was detected 
in 37% of  ESCC. One potentially relevant gene at 17p is 
TP53, whose product contributes to the control of  cell 
proliferation and malignant transformation. Inactivation 
of  TP53 is the most common defect found in human 
cancer including ESCC from Henan, China. Loss of  1p 
occurred in 32%. The minimal common region of  deletion 
encompasses the most distal band 1p36-pter in ESCC. 
Loss of  chromosome band 1p36 is frequently found in 
many malignancies, including gastric cardia carcinoma, 
colon cancer, and ESCC[20]. 
In 15 pairs of  ESCC and their corresponding 
metastatic lymph nodes, the most interesting finding in this 
study is the gain of  6p12-6q21 detected in seven metastatic 
lymph node lesions but only in two corresponding primary 
tumors (13% vs 47%; P = 0.05). This suggests that 6p 
may harbor a putative oncogene that plays an important 
role in the ESCC progression, especially in the lymph 
Table 2  CGH results of lymph node metastasis, Linzhou, Henan
Case No. Gains Losses
16 148 2p12-2q32, 3p12-3qter, 5p, 9q 3pter-3p13, 5q31-5qter,X
L16 148 1q, 2q11-2q31, 3q, 5p, 9p12-9qter, 12,20 2q32-2qter, 3p, 4,5q, 6pter-6p22, 19,X
16 668 3q13-3qter, 4q31-4qter, 7pter-1p11, 8q12-8qter, 18p 1p, 4pter-4p14, 4q21-4q28, 7q22-7qter, 9p
L16 668 3q, 4p12-4q13, 7p15-7q22, 8p21-8qter, 13,15pter-15q15, 18pter-18q12, 20pter-20q12 3p, 4pter-4p13, 4q13-4q25, 7q31-7qter, 9p, 11q13-11qter
16 669 3p12-3qter, 7p, 8q, 12pter-12q13, 14 1p, 3pter-3p12, 4p, 10,11,17,19
L16 669 3p12-3qter, 6p12-6q14, 7p, 8p12-8qter, 14,20p11-20qter 1p, 3pter-3p12, 4p, 10,11,19
16v688 1q21-1qter, 3q, 5p, 6p12-6q24, 7q11-31, 8p22-8q23, 11q, 11q11-11q14, 18pter-18q12 3p, 4q13-4qter, 6pter-6p21, 7q32-7qter, 9p12-9qter, 10p, 
11p, 16q, 17pter-17p11, 17q22-17qter, 19
L16 688 1p13-1qter, 1p13-1q21, 2,3q, 6p21-6q12, 8q11-8q23, 11q, 11q11-11q14, 12p, 
18pter-18q11, 18p11-18q11, 20
3p, 4,5pter-5q15, 6pter-6p21, 6q16-6qter, 7p, 7q31-7qter, 
8pter-8p12, 9q, 10p, 11p, 13,17p, 17q22-17qter, 19,21
16 691 1q, 2pter-2q21, 3q, 11q11-11q13, 13q14-13qter, 16q11-16q13, 17q21.1-21.3, 20 3p, 8q11-8q22, 9q, 11q14-11qter, 13pter-13q14, 16p, 
19,21,22
L16 691 1q, 2pter-2q21, 3q, 11q11-11q13, 13q14.3-13qter, 16q11-16q13, 17q21.1-17q21.3, 20 1pter-1p32, 3p, 8q11-8q22, 9q, 11q14-11qter, 
13pter-13q14.2, 16p, 17p, 19,21,22
16 670 3q, 8q, 12p, 14,16p11-16q21, 18p, 20 1pter-1p31, 9p12-9qter, 17,18q, 19,Y
L16 670 3q, 8q, 12p, 14,18p, 20 1pter-1p34, 3pter-3p13, 9q, 10,11p11-11q12, 17,19p,Y
16 710 1p33-1qter, 2pter-2q32, 3p13-3qter, 5pter-5q12, 6q16-6qter, 7p, 11q11-11q23, 
12pter-12q15, 13,16p13-16qter, 17p,
4p, 18pter-18q21
L16 710 1q, 2p22-12, 2q22-2q32, 3q, 5p, 6q21-6qter, 7p, 9pter-9p21, 11q11-11q14, 13,16q, 
17pter-17q12
1p, 4,6pter-6q16, 8pter-8p12, 10pter-10p12, 
10q23-10qter, 11p, 11q14-11qter, 12q, 16p, 18,21
16 727 1p13-1q24, 2p24-2p23, 2p14-2p12, 3q13-3qter, 5p, 7q11-7qter, 8q, 12pter-12q12, 
14q23-14qter, 18pter-18q12, 20
1p, 2q32-2qter, 3pter-3p21, 4,5q, 8p, 11p, 18q12-qter
L16 727 1q, 2p14-2p11, 3q13-3qter, 5p, 7q11-7qter, 8q, 12pter-12q13, 14,17q, 18p, 20p 1p, 2q32-2qter, 3p, 4,5q, 9p, 10p, 11p, 15pter-15q22, 
18q12-18qter, 21
16 728 3q, 8p12-8qter, 11p11-11q14, 12pter-12q12, 16p, 18pter-18q12, 20 3p,Xp
L16 728 1p21-1pter, 3q, 3q24-3qter, 7p12-7q22, 8q, 8q21-8qter, 12p12-12q12, 14q11-14q21, 20p 4q, 8pter-8p22, 10,11,13q12-13q31, 14q23-14qter, 20q,Xp
16 730 1q, 3q, 6,7,8,12pter-12q13, 20q12-20qter 3p, 9p, 16q, 19p13-19q13
L16 730 1q, 2,3q, 6,6p21-6q13, 12pter-12q14, 18p11-18q12 1p, 3p, 4q26-4qter, 5q, 9,10,13,16,18q21-18qter, 19p, 21
16 731 3q, 4p13-4q13, 16q11-16q12, 11p13-11q13, 12 9,13
L16 731 3q, 4p13-4q13, 8p12-8qter 3p21-3p11, 9q, 10,17,18q12-18qter, 19
16 738 1q, 3p13-3qter, 5p, 8q 1pter-1p31, 3pter-3p14, 4,11,16,17,19,Xpter-q21
L16 738 1p13-1qter, 1p13-1q21, 5pter-5q12, 6p21-6q14, 8q, 20 1pter-1q13, 2pter-2p21, 3p, 4,8p, 11pter-11p12, 
11q14-11qter, 13,16p, 17,18, Xpter-q21
16 742 1q11-1q24, 3q, 3q24-3qter, 5pter-5q12, 8p11-8qter, 9q, 10p, 12p, 19p12-19q12, 20 1p, 3p, 4,6q16-6qter, 8pter-8p12, 9p, 10q22-10qter, 
11,13,14q21-14qter
L16 742 1q11-1q24, 2p21-2qter, 3q, 3q22-3qter, 5p13-5q13, 7,8q, 9q21-9q32, 10p12-10q11, 
12pter-12q13, 20
1qter-1q32, 3p, 4,6q, 8p, 10q21-10qter, 11,12q21-12qter, 
13,14q21-14qter, 19
16 745 1q, 2q24-2q33, 3q, 5p, 6q13-6q24, 8,9p, 10pter-10q21, 12q14-12q21 1pter-1p32, 2q21-2q24, 2q34-2qter, 3p, 4,5q, 7q31-7qter, 
11q14-11qter, 13pter-13q21, 16,18,19,21
L16 745 1q, 2q24-2q35, 3q, 5p, 6p21-6q25, 8 2q21-2q24, 2q34-2qter, 3p, 4,5q, 7q31-7qter, 11q14-
11qter, 13pter-13q21, 16,18,19,21
16 770 3p12-3qter, 8p12-8qter 17p, 19p, 22
L16 770 3q, 6p, 16p11-16q21, 18p, 20 11,13,17p, 18q, 19p, 22
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node metastasis. One study shows that regions 6p12-q14 
harbor the CCND3 gene, which shares 53.1% homology 
to CCND1. The CCND1 gene is amplified in 30% of  
ESCC[21]. Regions of  6p12 are found to harbor runt-related 
transcription factor (RUNX) gene, which is associated with 
cell migration and invasion[22]. The gain of  6p is frequently 
detected in CGH studies in other tumors including uveal 
melanoma and Barrett’s adenocarcinoma[23,24]. Most 
interestingly, in three cases, the high-level amplification of  
6p12 was detected only in metastatic tumors. This implies 
that the overexpression of  an oncogene(s) at 6p12 confers 
a selective advantage in ESCC. Moreover, this finding 
provides a candidate minimum amplification region 
at 6p12 for further studies and gene cloning. Another 
interesting finding in this study is the gain of  20p that 
was detected in 11 metastatic lymph node lesions but only 
in five corresponding primary tumors. The difference is 
significant in 20p gain between primary tumors and their 
metastatic lymph node lesions of  ESCC (40% vs 73%, 
P = 0.03). This suggests that 20p may harbor an oncogene 
and play an important part in ESCC progression especially 
in lymph node metastasis. Little is known about the 
relationship between 20p and the lymph node metastasis 
of  ESCC. Heselmeyer et al demonstrated that gains of  
6p and 20p were connected with advanced-stage cervical 
carcinomas[25]. Hu et al demonstrated the over-expression 
of  CDC25B gene in ESCC[26]. Possible candidate gene 
on 20p includes CDC25B and proliferating cell nuclear 
antigen (PCNA), each of  which plays an important role at 
specific stages of  cell cycle progression.
Loss of  10p was seen in eight metastatic lymph nodes 
but only in two corresponding primary tumors. The 
difference between primary tumors and their metastatic 
lymph node lesions of  ESCC was significant (13% vs 53% 
P = 0.05). Loss of  10q was detected in seven metastatic 
lymph nodes but only in two corresponding primary 
1                                                       2                                                      3                                                                       4
5                                        6                                      7                                       8                                                      9
10                                          11                     12                                       13                   14                 15                  16
17                        18                                                  19          20                                         21       22          γ                     χ 
Figure 2  Copy number gains and losses in ESCC by CGH. Chromosomal localization of gains is on the right side of chromosome ideograms and that of losses are on the 
left side. Thick lines indicate amplified regions. Straight lines indicate lymph nodes metastasis. Conversely primary tumors are indicated by dotted lines.
Table 3  Chromosomal aberrations with primary ESCC and 
lymph node metastasis
Chromosomal changes Primary 
tumor (%)
Lymph node 
metastasis %
P 
value
Gain of 6p 2/15 (13)   7/15 (47) 0.05
Gain of 20p 5/15 (40) 11/15 (73) 0.03
Loss of 10p 2/15 (13)   8/15 (53) 0.05
Loss of 10q 2/15 (13)   7/15 (47) 0.05
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tumors. The difference between primary tumors and their 
metastatic lymph node lesions of  ESCC was significant 
(13% vs 47% P = 0.05). These alterations had also been 
found in other carcinoma metastases, such as the head-
neck squamous cell carcinoma (HNSCC)[27] and Spitzoid 
malignant melanoma[28]. A role of  the 10q deletion in 
tumor progression is however conceivable since additional 
germline mutations in the PTEN gene (on chromosome 
10q23) have been shown to be present in Crowden’s 
disease[29].
In this study, more genetic changes were found in 
lymph node metastasis than in their corresponding 
primary lesions, especially the losses (9.5/case vs 6.0/case). 
Previous studies showed that DNA copy number losses 
were more common in the metastases than in the primary 
larynx tumors and HNSCC[30,31]. In ESCC, DNA losses 
seem to be more closely associated with metastases than 
DNA amplification.
In conclusion, using the CGH technique to detect 
chromosomal aberrations in both the primary tumor 
and its metastatic lymph nodes of  ESCC, gains of  8q, 
3q, 5p and losses of  3p, 8p, 9q and 13q were specifically 
implicated in ESCC in Linzhou population.  Furthermore, 
gains of  6p, 20p and loss of  10pq may contribute to the 
lymph metastasis of  ESCC. These findings suggest that 
the gains and losses of  chromosomal regions may contain 
ESCC-related oncogenes and tumor suppressor genes. 
The gains and losses of  chromosomal regions identified 
in this study provide important theoretic information for 
identifying and cloning novel ESCC-related oncogenes 
and tumor suppressor genes. Finally, this study provides a 
practicable model to detect specific genetic change related 
to tumor metastasis by comparing the primary tumor 
with its corresponding metastatic tumor using the CGH 
technique.
 COMMENTS
Background
Esophageal squamous cell carcinoma (ESCC) is one of the leading causes 
of cancer-related death in Linxian, Henan Province in northern China, with a 
mortality rate of 161/100 000 for male and 103/100 000 for female. However, 
the mechanisms of human esophageal multistage carcinogenesis in this area, 
especially the difference in genetic changes between primary ESCC and 
metastatic lymph nodes are largely unknown.
Research frontiers
In this study, the authors applied comparative genomic hybridization (CGH) 
to ESCC to elucidate genetic aberrations in carcinogenesis and lymph node 
metastasis. To the knowledge of the authors, though CGH analysis of ESCC has 
been reported, no information is available concerning the relationship between 
genetic changes and the biologic characteristics of ESCC. The gains of 3q, 5p, 
8q23-ter and 20q and deletions of 3p25, 4p, 6q21, 9q22.3-q31, 9p, 11q22-qter, 
13q12-13, 18q22.3, and 19q had been detected as most frequent chromosomal 
alterations in ESCC. Our CGH results are generally consistent with other CGH 
studies.
Innovations and breakthroughs
The present CGH study provides the first record of chromosomal imbalances 
occurring in ESCC tumors and corresponding lymph nodes in Linxian, Henan 
Province in northern China. The major findings of this paper are that gains of 8q, 
3q, 5p and losses of 3p, 8p, 9q and 13q were specifically implicated in ESCC in 
Linzhou population, and gains of 6p, 20p and loss of 10pq may contribute to the 
lymph metastasis of ESCC. These loci may harbor the genes in the development 
and /or progression of ESCC. 
Applications 
These loci provide important theoretic information for identifying and cloning 
novel ESCC-related oncogenes and tumor suppressor genes. Further studies 
are necessary to identify specific genes of these chromosomal regions and their 
functions. The target tumor susceptibility genes will be further characterized 
by mutation analysis. Single strand conformation polymorphism (SSCP) and 
sequencing analysis will be used to screen the mutation.
Terminology
Comparative genomic hybridization (CGH); Single strand conformation 
polymorphism (SSCP).
Peer review
This is a nicely written and presented paper with 37 cases of primary esophageal 
cancer and matched metastatic tissues. Although the number of studied cases is 
small, it is a useful contribution to the literature.
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